Efficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis SuppurativaJoin-Lambert O.a, b, j, k · Coignard H.a, c, k · Jais J.-P.a, d · Guet-Revillet H.a, b, j, k · Poirée S.a, e · Fraitag S.a, f · Jullien V.a, g · Ribadeau-Dumas F.h, k · Thèze J.h, k · Le Guern A.-S.h, k · Behillil S.h, k · Leflèche A.i · Berche P.a, b, k · Consigny P.H.h, k · Lortholary O.a, c, k · Nassif X.a, b, j, k · Nassif A.h, k
aUniversité Paris Descartes, Faculté de Médecine Paris Descartes, bLaboratoire de Microbiologie, cService des Maladies Infectieuses et Tropicales, dService d’Informatique Médicale et de Biostatistiques, eService de Radiologie Adulte, fService d’Anatomie et de Cytologie Pathologiques, Hôpital Necker-Enfants malades, Assistance-Publique-Hôpitaux de Paris, gService de Pharmacologie Saint-Vincent-de-Paul, Assistance-Publique-Hôpitaux de Paris, hCentre Médical, iCellule d’Intervention Biologique d’Urgence Institut Pasteur (CIBU), jINSERM U1002 and kCentre d’Infectiologie Necker-Pasteur, Paris, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Antibiotics have been shown to improve hidradenitis suppurativa (HS) patients but complete remission is rare using these treatments. Objective: To assess the efficacy and safety of a combination of oral rifampin, moxifloxacin and metronidazole in long-lasting refractory HS. Methods: We retrospectively studied 28 consecutive HS patients including 6, 10 and 12 Hurley stage 1, 2 and 3 patients, respectively. Complete remission, defined as a clearance of all inflammatory lesions including hypertrophic scars, was the main outcome criterion of the study. Results: Complete remission was obtained in 16 patients, including 6/6, 8/10 and 2/12 patients with Hurley stage 1, 2 and 3, respectively (p = 0.0004). The median duration of treatment to obtain complete remission was 2.4 (range 0.9–6.5) and 3.8 months (range 1.6–7.4) in stage 1 and 2 patients, respectively, and 6.2 and 12 months in the 2 stage 3 patients. Main adverse events of the treatments were gastrointestinal disorders (64% of patients) and vaginal candidiasis (35% of females). Reversible tendinopathy and hepatitis occurred in 4 and 1 patient, respectively. Conclusions: Complete remission of refractory HS can be obtained using broad-spectrum antibiotics and Hurley staging is a prognostic factor of response to the treatment.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.